• Title, Summary, Keyword: Somatotropin

Search Result 71, Processing Time 0.136 seconds

The Structural Characterization of Recombinant Bovine Somatotropin Expressed in Escherichia coli (재조합 소성장호르몬의 구조적 특성)

  • 김정호;김훈주박은숙김준
    • KSBB Journal
    • /
    • v.9 no.2
    • /
    • pp.165-173
    • /
    • 1994
  • In this paper we have described the structural characterization of recombinant bovine somatotropin produced in Escherichia coli. Recombinant bovine somatotropin consists of 191 amino acid residues with a calculated molecular weight of 21,802 Da. For fragmentation of recombinant bovine somatotropin, we have used trypsin, Staphylococcus aureus V8 pretease, CNBr, and mild acid hydrolysis method. Digestion and cleavage with these proteases and chemicals yielded peptides of various size for amino acid sequence determination. The N-terminal sequence analysis was carried out up to thirty residues. Because the design of the recombinant bovine somatotropin gene for expression was such that the coding sequence begins with an initiation codon, AUG, before Ala, the first amino acid of bovine somatotropin, we could expect the initial amino acid as N-formyl Met. But the first amino acid of this protein, expressed in E. coli cells as inclusion bodies, was Ala. And the amino acid composition of RP-HPLC purified recombinant bovine somatotropin was determined and no essencial difference was observed. The amino acid sequence of the recombinant bovine somatotropin was identical to that predicted from its recombinant gene. There was no processing or replacement of amino acid residues in recombinant bovine somatotropin expressed in E. coli. The hydropathy plot of recombinant bovine somatotropin revealed a hydrophobic region at the NH2-terminus and hydrophilic region at the COOH-terminus. The E. coli expression system is thought to be valuable for the expression of recombinant bovine somatotropin because protein was processed to remove the N-terminal Met residue by methionyl-aminopeptidase autonomously.

  • PDF

Blood profile test of sustained release formula of implantable bovine somatotropin in steers (비육우에서 이식형 bovine somatotropin 지속성 제형의 blood profile test)

  • Kim, Nam Joong
    • Korean Journal of Veterinary Research
    • /
    • v.49 no.1
    • /
    • pp.9-15
    • /
    • 2009
  • The present study was carried out to examine the sustained release effect of the implantable bovine somatotropin (SRI-BST) formula. In the blood profile test in steers, the bovine somatotropin concentration in serum by radioimmunoassay showed the peak concentration on the first day after the implantation of the SRI-BST formula, and concentration proceeded for 5 days (p < 0.05). The insulin-like growth factor-1 concentration showed the peak concentration on the seventh day after implantation of the SRIF-BST formula, and concentration proceeded for 10 days (p < 0.05). The glucose showed the peak concentration on the first day after implantation of the SRI-BST formula, and concentration continued for 3 days (p < 0.05). The blood urea nitrogen showed the lowest concentration on the third day after implantation of the SRI-BST formula, and concentration continued for 7 days (p < 0.05). These results proved that the SRIF-BST formula was the sustained release effects in steers.

Effect of Recombinant Bovine Somatotropin Administration on Bovine Somatotropin Levels in Cow Milk (유전자재조합 Bovine Somatotropin 투여가 우유중의 Bovine Somatotropin 농도에 미치는 영향)

  • 최정은;최명자;진재호;김주호;박종세
    • Journal of Food Hygiene and Safety
    • /
    • v.10 no.2
    • /
    • pp.61-64
    • /
    • 1995
  • The present study was conducted to examine the effect of recombinant bovine somatotrpin(${\gamma}$BST), which was administered to cow to promote milk production, on bST levels in milk. Fourteen cows were divided cows were divided into two groups: 1) control cows received neither ${\gamma}$bST nor vehicle, 2) treated cows were administered twice at two-week interval with 500 mg ${\gamma}$bST each cow byj after lst injection. Milk samples were taken on day 0 (prior to injection), day 7 (7 days after lst injection), day 21 (7 days after 2nd injection) and day 35 (21 days after 2nd injection). Milk bST concentration was measured by the radioimmunoassay method. There was no statistical difference(p<0.05) in milk bST levels between two groups showing bST levels in the range of 1.8 ng/m/ to 3.1 ng/m/. That is, ${\gamma}$bST administration did not increase bST levels in milk.

  • PDF

Development and sustained release effect of implantable formula of somatotropin (Somatotropin 이식 제형 개발과 지속적 방출 효과)

  • Kim, Nam-Joong
    • Korean Journal of Veterinary Research
    • /
    • v.48 no.1
    • /
    • pp.27-32
    • /
    • 2008
  • The present study was carried out to develop a sustained release implantable formula of bovine somatotropin (SRIF-BST) and to examine its sustained release effect. The SRIF-BST was produced by coating a solid pellet, which was comprised of BST and an excipient, made of a biodegradable polymer and poloxamer, which are capable of regulating the rate of BST release. The coated membrane of SRIFBST was observed with a field emission scanning electron microscope. The thickness of the coated membrane was approximately $1{\mu}m$, and the pore sizes of the coated membrane surface were below $10{\mu}m$. In dissolution test, the release duration of the SRIF-BST maintained for 10 days, whereas the release duration of the control BST formula maintained for 3 days. In weight gain assay and tibia test of hypophysectomized rats, the release duration of the SRIF-BST treated group was 12 days and the net weight gain was 53.16 g, also the tibia length and strength of the SRIF-BST treated group was increased 10.5% and 23.1% compared with those of the control group, respectively.

EFFECT OF RECOMBINANT BOVINE SOMATOTROPIN ON MILK PRODUCTION AND MILK COMPOSITION IN DAIRY COWS

  • Myung, K.H.
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.3 no.3
    • /
    • pp.247-252
    • /
    • 1990
  • Nine Holstein cows in mid lactation period were utilized to examine the effect of recombinant bovine somatotropin (BST) of tow companies (Company A, Company B) on milk production and milk composition under the feeding conditions of Korea. Treatments were 0 (Control), 25 mg BST/day from company A (BST A) and 25 mg BST/day from company B (BST B) injected subcutaneously, once daily beginning at $200{\pm}20$ days postpartum and continuing for 28 days. Cows were fed ad libitum a total mixed diet throughout the experimental period. BST treatments increased average 4% fat corrected milk yields and milk energy output over the 28-day treatment period. However, no differences were observed in dry matter intake, gross efficiency, energy intake and percent milk energy. Although there was a tendency for increased milk fat percent, there were no differences in milk composition and yields of major milk components except for milk fat yield with BST injection. Somatic cells of all groups were also characteristic of a well managed herd. Neither mean body condition score nor body weight was significantly (p <0.05) changed before and during BST treatment. BST concentration in milk remained in the range of control animals throughout the experimental period of BST treatment. Results indicate that short-term injection of recombinant bovine somatotropin from two companies to lactating dairy cow resulted in similar increased in milk yield without alteration of major milk components or feed intake.

Efficacy test of sustained-release somatotropin by implantation in steer, cow and barrow (비육우, 젖소 및 비육돈에서 이식형 소마토트로핀 지속성 제형의 유효성 시험 연구)

  • Kim, Nam Joong
    • Korean Journal of Veterinary Research
    • /
    • v.51 no.1
    • /
    • pp.1-6
    • /
    • 2011
  • Sixteen steers were used to investigate the efficacy of the sustained-release implant of bovine somatotropin (bST) in improving growth and feed:gain ratio during 12 weeks. Administration of the 400 mg bST implant resulted in a 16.1% increase in growth rate, and this increase was significant (p<.05). The use of the sustained-release implant did not alter (p>.05) feed intake and feed:gain ratio. Thirty-four cows were used to investigate the efficacy of the sustained-release implant of bST in milk production during 4 weeks. Administration of the 200 mg bST implant resulted in an 8.7% increase in milk production, and this increase was significant (p<.05). Twenty-four barrows were used to investigate the efficacy of the sustained-release implant of porcine somatotropin (pST) in improving growth, feed:gain ratio and backfat thickness during 6 weeks. Administration of the 120 mg pST implant resulted in a 11.4% increase in feed:gain ratio and a 60% decrease in backfat thickness, and these results were significant (p<.05). But the use of the sustained-release implant did not alter (p>.05) growth rate and feed intake.

Effects of Exogenous Bovine Somatotropin on Mammary Function of Late Lactating Crossbred Holstein Cows

  • Tanwattana, P.;Chanpongsang, S.;Chaiyabutr, N.
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.16 no.1
    • /
    • pp.88-95
    • /
    • 2003
  • The objective of the present study was to determine the effect of exogenous bovine somatotropin on the mammary function in late lactating crossbred Holstein cows. Twelve 87.5% late lactating Holstein cows, approximately 30 weeks postpartum, were divided into two groups of 6 animals each. Animals in the control group were given sodium bicarbonate buffer by subcutaneous injection, while animals in the treated group were given recombinant bovine somatotropin (bST) by subcutaneous injection with 500 mg of bST (14 day prolonged-release bST). After bST injection, milk yield significantly increased from the control level on day 8 to day 20 (p<0.05) with a concomitant increase in mammary blood flow (p<0.01). An increase in mammary blood flow in response to bST treatment was greater than an increase in milk production. An increased plasma concentration of IGF-I coincided with an increase in mammary blood flow in animals treated with bST. There were no significant changes in the concentration of arterial plasma glucose concentration, the arteriovenous concentration difference (A-V difference) and mammary extraction ratio while the mammary glucose uptake increased when compared to the control group. The concentration of arterial plasma triglyceride decreased throughout the experimental period in animals give bST. The plasma concentration of acetate, and the mammary uptake for acetate significantly increased (p<0.05) after bST treatment. The action of bST did not affect the plasma concentration, A-V difference and extraction ratio across the mammary gland for $\beta$-hydroxybutyrate. The concentrations of milk fat and lactose tended to increase during bST treatment. Milk protein concentration initially increased in the first few days and decreased after bST injection when compared to the pretreated period. The present results indicated that bST could affect the mammary function in late lactating cows by increase in milk yield involving changes in both extra-mammary and intra-mammary mechanisms. The exogenous bST exerted its galactopoietic action through an increase in circulating IGF-I of the late lactating Crossbred Holstein cattle.